Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act

This is a long-duration re-rating story, not an immediate fundamental inflection. The market will likely assign most of the value to probability-weighted pipeline optionality until there is either a clean FDA interaction or proof that the balance sheet can carry the company through the 2026-27 milestones without punitive dilution. In that sense, the near-term winner is management credibility; the loser is the generic small-cap biotech basket if capital rotates toward names with nearer-term de-risking.

Ozekibart is the cleaner asset because it can support a regulatory framework, but the commercial ceiling is still constrained by orphan-disease math unless the label broadens or the data translate into a partnerable platform. INBRX-106 is more valuable as a strategic bridge to a bigger immuno-oncology story than as a near-term revenue driver; if the early signal holds, it could attract BD interest from large oncology franchises, but that outcome is months away and highly sensitive to trial design and competitive readthrough.

The contrarian issue is dilution risk: the consensus may be underwriting a binary upside path while underestimating the cost of carrying two late-stage programs for 12-18 months. Any weak financing terms, CMC hiccup, or FDA delay would hit the equity harder than the science would suggest, because the valuation is concentrated in a small number of future events. Conversely, a disclosed runway extension or partnership would be the main falsifier for a bearish view.